Ligand Pharmaceuticals Inc. (LGND)
Summary
Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator
Ligand Pharmaceuticals has delivered exceptional long-term returns, rising from ~$86 to nearly $300 over six years. Recent developments include a significant Xoma acquisition and portfolio advancements. I closely review LGND's Q1 2026 earnings, highlighting operational and financial performance and strategic moves.
Ligand Pharmaceuticals Q1 Earnings Call Highlights
Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key commercial products and the pending acquisition of XOMA Royalty Corporation.
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
Ligand Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 1,010 | $177,493.82 | $300,262.9 | $122,769.08 | 69.17% |
| CE Curtis Ellergodt Rothschild Investment LLC | 433 | $31,903.87 | $128,726.57 | $96,822.7 | 303.48% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 694 | $138,557.1 | $207,020.2 | $68,463.1 | 49.41% |
| BG Bart Gancher Intech Investment Management LLC | 6,087 | $767,252.16 | $1.82M | $1.06M | 137.74% |
 Private Capital Private Capital Management | 201,381 | $19.65M | $60.22M | $40.56M | 206.39% |
Ligand Pharmaceuticals Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JZ Jason Zemansky B of A Securities | 309.97 | $100,000 | $92,092.62 | -$7,907.38 | -7.91% |
 Yigal Nochomovitz Citigroup | 16.47 | $4,375.07 | $4,882.69 | $507.62 | 11.6% |
| RW Robert Wasserman Benchmark | - | - | - | - | - |
Ligand Pharmaceuticals Inc. (LGND) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ligand Pharmaceuticals Inc. ever had a stock split?
Ligand Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Todd C. Davis CEO | NASDAQ (NMS) Exchange | 53220K504 CUSIP |
| US Country | 47 Employees | 2 Jul 2010 Last Dividend | 2 Nov 2022 Last Split | 18 Nov 1992 IPO Date |
Overview
Ligand Pharmaceuticals Incorporated is a pioneering biopharmaceutical company focused on the development and licensing of innovative biopharmaceutical assets on a global scale. With a rich history since its inception in 1987, the company has established itself as a key player in the healthcare sector. Based in Jupiter, Florida, Ligand Pharmaceuticals has forged strong alliances, licenses, and business relationships with several major industry leaders, including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. One of its notable contributions is the sale of Captisol materials, which are designed to improve the solubility and stability of drugs.
Products and Services
Kyprolis and Evomela: These are therapeutic products used in the treatment of multiple myeloma, providing vital options for patients with this challenging condition.
Rylaze: This recombinant erwinia asparaginase is designed for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in both adults and pediatric patients, marking a significant advancement in leukemia therapy.
Filspari: A dual endothelin and angiotensin II receptor antagonist, currently in development stages for rare kidney diseases and as a non-immunosuppressive treatment for immunoglobulin A nephropathy.
Teriparatide injection product: This product offers a treatment solution for osteoporosis, aiming to improve bone strength and reduce the risk of fractures.
Vaxneuvance and Pneumosil: These vaccines are intended for the prevention of invasive diseases caused by certain streptococcus pneumoniae serotypes. Vaxneuvance targets a broad range, while Pneumosil focuses on protecting children from pneumococcal pneumonia.
TZIELD: A CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 type 1 diabetes, representing a proactive approach to managing this disease.
Nexterone: A captisol-enabled formulation of amiodarone, providing a safer and more effective treatment options for those requiring this critical cardiovascular medication.
Zulresso: A captisol-enabled formulation of brexanolone for the treatment of postpartum depression, offering new hope for mothers struggling with this severe condition.
Veklury: This antiviral treatment is utilized for the management of moderate or severe COVID-19, playing a significant role in the global pandemic response.
Noxafil-IV: A captisol-enabled formulation of posaconazole for intravenous use, aimed at fighting against severe fungal infections.
Duavee: A treatment for post-menopausal symptoms in women, providing relief and comfort for those dealing with the effects of menopause.
Exemptia, Vivitra, Bryxta, and Zybev: These products span various indications, including autoimmune diseases, breast cancer, and other conditions, showcasing Ligand Pharmaceuticals' versatility in addressing a wide range of health issues.
